RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) vs Veeva Systems — how do they compare? RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $37.8 (market cap $63.89B), while Veeva Systems trades at $298.35 (market cap $48.84B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is the larger of the two by market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays a 2.47% dividend while Veeva Systems pays none. Which is the better fit depends on your goals.
| RELX | VEEV | |
|---|---|---|
Market Cap | $63.89B | $48.84B |
Volume | 2,760,502 | 2,253,175 |
Sector | Industrials | Technology |
52-Week High | $46.80 | $301.63 |
52-Week Low | $27.73 | $151.43 |
Enterprise Value | $75.40B | $41.75B |
Dividend Yield | 2.47% | — |
Typical Hold Time | — | 6 Days |
Signals from Pluang's Aura AI — not financial advice
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Veeva Systems (VEEV) trades at $301.63, up 1.95% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 74.96% gross margins and consistent earnings beats, while expanding partnerships with IQVIA and Servier enhance growth prospects. Recent news highlights AI innovations and increasing adoption among biotech firms, supporting positive sentiment.
Outlook remains favorable with analyst consensus at Buy (67% rating) and $290.50 price target, though valuation multiples appear elevated. Key risks include market saturation concerns and potential volatility from RSI overbought signals. The stock's proximity to 52-week highs suggests continued investor confidence in Veeva's life sciences software leadership.
Trailing returns across standard periods
Latest headlines on both assets
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →